ResMed, Inc. (NYSE: RMD) reported Q3 EPS of $0.63, $0.01 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $397.8 million versus the consensus estimate of $401 million.

For earnings history and earnings-related data on ResMed, Inc. (RMD) click here.